Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Introduction: Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological underpinnings of the mechanism of antidepressant action of these drugs. Methods: A narrative review was conducted using PubMed to identify published articles evaluating the antidepressant mechanism of action of serotonergic psychedelics. Results: Serotonergic psychedelics have serotonin (5HT)2A agonist or partial agonist effects. Their rapid antidepressant effects may be mediated—in part—by their potent 5HT2A agonism, leading to rapid receptor downregulation. In addition, these psychedelics impact brain derived neurotrophic factor and immunomodulatory responses, both of which may play a role in their antidepressant effect. Several neuroimaging and neurophysiology studies evaluating mechanistic change from a network perspective can help us to further understand their mechanism of action. Some, but not all, data suggest that psychedelics may exert their effects, in part, by disrupting the activity of the default mode network, which is involved in both introspection and self-referential thinking and is over-active in MDD. Conclusion: The mechanisms of action underlying the antidepressant effect of serotonergic psychedelics remains an active area of research. Several competing theories are being evaluated and more research is needed to determine which ones are supported by the most robust evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with SSRIs, their enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 2×
“Similar findings are reported for other inflammatory markers such as IL-1β, CRP, and TNF-α (50, 53).”
BackgroundRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“SSRIs increase neurogenesis (40) and their behavioral effects can be blocked by its disruption (41).”
BackgroundThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“Depressive symptoms have been linked to insufficient neurogenesis and neurotrophic activity (39).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
A functional anatomical study of unipolar depression
Drevets, W., Videen, T., Price, J., Preskorn, S., Carmichael, S., & Raichle, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03628.1992 · Cited by 1,266
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“Similarly, magnetoencephalography (MEG) shows broadband desynchronization of cortical oscillatory rhythms and decreases in network integrity after ingestion of psilocybin (89), supporting that psychedelics can disorganize spontaneous brain activity (58, 89).”
BackgroundShimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 9×
“Antidepressants (31), sleep, and physical exercise increase BDNF (32, 33).”
BackgroundInfluentialPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“This effect can be blocked by administering 5-HT2AR antagonists, such as ketanserin or risperidone (19).”
BackgroundNeural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 1×
“In participants who ingested LSD, EEG, and MEG studies have also showed a relationship between decreased alpha power and the hallucinatory experience and subjective reports of ego dissolution (87, 90).”
BackgroundPalhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
National Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 1×
“, weight gain, sexual dysfunction) (4, 5).”
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661
How do antidepressants work? New perspectives for refining future treatment approaches
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616
Monoamine neurocircuitry in depression and strategies for new treatments
Hamon, M., & Blier, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.009 · Cited by 594
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · cited 1×
“While it has been proposed that the hallucinogenic experience and associated “mystical effects” produced by 5-HT2AR agonism are responsible for the antidepressant effect (23), there is little evidence to support this.”
BackgroundIncreased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 1×
“These increases have been observed in healthy volunteers after administration of psilocybin (56, 61, 84) or LSD (60, 62), particularly in areas rich in 5-HT2AR (60).”
BackgroundPrevalence and predictors of recurrence of major depressive disorder in the adult population
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W. A., & Beekman, A. T. F. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01519.x · Cited by 486
Broadband Cortical Desynchronization Underlies the Human Psychedelic State
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2063-13.2013 · Cited by 475
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Increased global integration in the brain after psilocybin therapy for depression
(2022) · doi:10.1038/s41591-022-01744-z · Cited by 445
Continuity of antidepressant treatment for adults with depression in the United States
Olfson, M., Marcus, S. C., Tedeschi, M., & Wan, G. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.101 · Cited by 392
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., Seifritz, E., Repovs, G., Krystal, J. H., Murray, J. D., et al. (2018) · eLife · doi:10.7554/elife.35082 · Cited by 390 · cited 1×
“Similar hyperconnectivity between the DMN and the occipital cortex has been reported in healthy volunteers after administration of LSD (64) or psilocybin (65), and between the amygdala and occipital cortex after administration of psilocybin (80).”
BackgroundReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378 · cited 1×
“In fact, in pre-clinical models of depression, psilocybin reverses anhedonia even when mice are pre-treated with the 5-HT2AR antagonist ketanserin (24).”
BackgroundDoss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01706-y · Cited by 356
Kometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355
A brain network model for depression: From symptom understanding to disease intervention
Li, B., Friston, K., Mody, M., Wang, H., Lu, H., & Hu, D. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12998 · Cited by 334
Decreased plasma BDNF level in depressive patients
Lee, B.-H., Kim, H., Park, S.-H., & Kim, Y.-K. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.11.005 · Cited by 326
Aydemir, O., Deveci, A., & Taneli, F. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.009 · Cited by 325
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Low plasma BDNF is associated with suicidal behavior in major depression
Kim, Y.-K., Lee, H.-P., Won, S.-D., Park, E.-Y., Lee, H.-Y., Lee, B.-H., Lee, S.-W., Yoon, D., Han, C., Kim, D.-J., et al. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.024 · Cited by 300 · cited 1×
“Decreased BDNF levels have been observed in MDD and correlate with suicidal behavior (29, 30).”
BackgroundHallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López-Giménez, J. F., & González-Maeso, J. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_478 · Cited by 299
Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis
Ma, Y. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.24 · Cited by 270
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267 · cited 1×
“A majority of immune cells express 5-HT receptors and it has been hypothesized that serotonergic psychedelics impact immunomodulatory agents through 5-HT2AR agonism (49).”
BackgroundEffects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“5-methoxy(MeO)-DMT (42) and psilocybin (43) increase neurogenesis in rats and the study involving psilocybin suggested this might be dose-dependent (43).”
BackgroundParachlorophenylalanine Reversal of Tranylcypromine Effects in Depressed Patients
Shopsin, B. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770070041003 · Cited by 265
Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis
Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., Sharp, D. J., Feilding, A., Wise, R. G., & Nutt, D. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs117 · Cited by 256 · cited 2×
“These increases have been observed in healthy volunteers after administration of psilocybin (56, 61, 84) or LSD (60, 62), particularly in areas rich in 5-HT2AR (60).”
BackgroundMethodDysfunction in the neural circuitry of emotional self-regulation in major depressive disorder
Beauregard, M., Paquette, V., & Le´vesque, J. (2006) · Neuroreport · doi:10.1097/01.wnr.0000220132.32091.9f · Cited by 254 · cited 2×
“Finally, “mystical experiences” may also play some role in relieving depressive symptoms but this has not yet been evaluated (74).”
BackgroundSmigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · cited 2×
“FC measures correlations between Blood-Oxygen-Level-Dependent (BOLD) signal fluctuations (55) as a proxy for brain activity (56).”
BackgroundMethodShort-term SSRI treatment normalises amygdala hyperactivity in depressed patients.
Godlewska, B. R., Norbury, R., Selvaraj, S., Cowen, P. J., & Harmer, C. J. (2012) · Psychological Medicine · doi:10.1017/s0033291712000591 · Cited by 244 · cited 2×
“This emotional release is thought to be facilitated by disruption of connectivity in regions with high density of 5-HT2ARs (75).”
BackgroundPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230 · cited 8×
“This is indirectly supported by the fact that most traditional antidepressants impact monoamines; for example, SSRIs acutely increase the availability of serotonin in synapses (16).”
InfluentialMertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208
Szabo, A., Kovacs, A., Frecska, E., & Rajnavolgyi, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106533 · Cited by 191
Barrett, F. S., Krimmel, S. R., Griffiths, R. R., Seminowicz, D. A., & Mathur, B. N. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.116980 · Cited by 188
Psychedelics: Where we are now, why we got here, what we must do
Belouin, S. J., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.018 · Cited by 187
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · cited 9×
“Antidepressants (31), sleep, and physical exercise increase BDNF (32, 33).”
BackgroundInfluentialPsilocybin Induces Time-Dependent Changes in Global Functional Connectivity
Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., Seifritz, E., Repovš, G., Krystal, J. H., Murray, J. D., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.12.027 · Cited by 183
Unifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 181
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
Serum BDNF levels before treatment predict SSRI response in depression
Wolkowitz, O. M., Wolf, J., Shelly, W., Rosser, R., Burke, H. M., Lerner, G. K., Reus, V. I., Nelson, J. C., Epel, E. S., & Mellon, S. H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.013 · Cited by 174
Altered network hub connectivity after acute LSD administration
Müller, F., Dolder, P. C., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.03.005 · Cited by 174
Shopsin, B., Gershon, S., Goldstein, M. N., Friedman, E., & Wilk, S. (1975) · PubMed · Cited by 157
Marek, G. J., & Aghajanian, G. K. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20792-3 · Cited by 152
Madsen, M. K., Stenbæk, D. S., Arvidsson, A., Armand, S., Marstrand-Joergensen, M. R., Johansen, S. S., Linnet, K., Ozenne, B., Knudsen, G. M., & Fisher, P. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.001 · Cited by 151
Hallucinogenic drugs in pre-Columbian Mesoamerican cultures
Carod-Artal, F. J. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.07.010 · Cited by 147
Pharmacology of ayahuasca administered in two repeated doses
dos Santos, R. G., Grasa, E., Valle, M., Ballester, M. R., Bouso, J. C., Nomdedéu, J. F., Homs, R., Barbanoj, M. J., & Riba, J. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2434-x · Cited by 141 · cited 1×
“Studies with ayahuasca suggest psychedelics may have immunomodulatory effects through decreasing white blood cells (CD4) and elevating natural killer cells (54).”
BackgroundWEISS, G., MURR, C., ZOLLER, H., HAUN, M., WIDNER, B., LUDESCHER, C., & FUCHS, D. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1999.00910.x · Cited by 139
Zhu, X., Zhu, Q., Shen, H., Liao, W., & Yuan, F. (2017) · Scientific Reports · doi:10.1038/srep43105 · Cited by 133
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131 · cited 1×
“A study using varying doses of LSD showed acute increases in BDNF only for certain doses (38), suggesting further investigation is needed.”
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128 · cited 2×
“Similar findings are reported for other inflammatory markers such as IL-1β, CRP, and TNF-α (50, 53).”
ResultAcute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Mueller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 127
Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01609.x · Cited by 125
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111953 · Cited by 123
Attentional bias in depression: understanding mechanisms to improve training and treatment
Mennen, A. C., Norman, K. A., & Turk-Browne, N. B. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.07.036 · Cited by 121
Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628430 · Cited by 118
Regulation of central 5-HT2A receptors: a review of in vivo studies
Eison, A. S., & Mullins, U. L. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00092-7 · Cited by 109
Fluoxetine-Induced Cortical Adult Neurogenesis
Ohira, K., Takeuchi, R., Shoji, H., & Miyakawa, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.2 · Cited by 90
Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination
Grimm, O., Kraehenmann, R., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.016 · Cited by 90
Murray, C. H., Tare, I., Perry, C., Malina, M., Lee, R., & de Wit, H. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05991-9 · Cited by 88
Lima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
McCulloch, D. E.-W., Madsen, M. K., Stenbæk, D. S., Kristiansen, S., Ozenne, B., Jensen, P. S., Knudsen, G. M., & Fisher, P. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211026454 · Cited by 83
Nkadimeng, S. M., Steinmann, C. M., & Eloff, J. N. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s317182 · Cited by 83 · cited 1×
“Congruent with this hypothesis, several in vitro studies have shown decreases of IL-6 in human cells following administration of DMT (50), 5-MeO-DMT (50), LSD (51), or psilocybin (52).”
BackgroundLu, J., Xu, Y., Hu, W., Gao, Y., Ni, X., Sheng, H., & Liu, Y. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.04.053 · Cited by 74
Smausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 70
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58 · cited 1×
“In rats repeated administration of ayahuasca increases hippocampal BDNF levels (35).”
Backgrounddos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Intrinsic Connectivity Networks in the Self- and Other-Referential Processing
Knyazev, G. G., Savostyanov, A. N., Bocharov, A. V., Levin, E. A., & Rudych, P. D. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.579703 · Cited by 45
Immunological Consequences of In Vitro Exposure to Lysergic Acid Diethylamide (LSD)
House, R. V., Thomas, P. T., & Bhargava, H. N. (1994) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923979409029898 · Cited by 43 · cited 1×
“Congruent with this hypothesis, several in vitro studies have shown decreases of IL-6 in human cells following administration of DMT (50), 5-MeO-DMT (50), LSD (51), or psilocybin (52).”
BackgroundVejmola, Č., Tylš, F., Piorecká, V., Koudelka, V., Kadeřábek, L., Novák, T., & Páleníček, T. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01603-4 · Cited by 41
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Taylor, A. P., Mortari, M. R., & Caldas, E. D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00854-w · Cited by 23
van Dam, W. O., & Chrysikou, E. G. (2021) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-020-00830-4 · Cited by 17
Grob, C. S., Bossis, A. P., & Griffiths, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-85702-8_5 · Cited by 11
Cited by
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“…enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29
Metadata
- Authors
- Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University Health Network (CA)
- Corresponding author
- Husain, Muhammad Ishrat
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-02-10
- Volume
- 13
- Pages
- 1076459-1076459
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC9950579
- OpenAlex
- W4319984222
- Cited by
- 50
- References
- 95
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 17 · 2023: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Patient-Centered Outcomes Research Institute
- Fondation Brain Canada
- Sunovion
- Indivior
- Centre for Addiction and Mental Health Foundation
- BrainsWay
- Physicians' Services Incorporated Foundation
- University of Toronto
- Grand Challenges Canada
- Servier
- H. Lundbeck A/S
- Seqirus
- National Institutes of Health
- Allergan
- Canadian Institutes of Health Research
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- serotonergic psychedelics, classic psychedelics, major depressive disorder, antidepressant mechanism, 5-HT2A receptor agonism, receptor down-regulation, brain-derived neurotrophic factor, immunomodulation, default mode network, neuroimaging, neurophysiology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.